secwatch.observer — SEC 8-K summary
======================================

Issuer:     Foghorn Therapeutics Inc. (FHTX)
CIK:        0001822462
Form:       8-K
Filed at:   2023-08-10T23:59:59+00:00
Accession:  0001628280-23-028846
Event type: other_material
Sentiment:  negative
Materiality: 0.70
Item codes: 1.02
LLM model:  deepseek-v4-flash:cloud@v2

Foghorn Therapeutics receives notice from Merck terminating collaboration agreement effective Nov 7, 2023
--------------------------------------------------------------------------------

- Merck terminates Research Collaboration and Exclusive License Agreement effective November 7, 2023, citing internal portfolio prioritization.
- Agreement granted Merck exclusive global rights to develop and commercialize drugs targeting a single transcription factor.
- Foghorn had received total of $20 million from Merck under the agreement (signed July 2, 2020).
- Foghorn loses potential future milestones and royalties from the collaboration.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1822462/000162828023028846/0001628280-23-028846-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1822462/000162828023028846/fhtx-20230809.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-028846

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer